Sponsor Pipeline

WEI XU Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
2
Active Trials
0
Recruiting
1
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-08-14 NCT07764601 R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Not Yet Recruiting
Active Trials by Phase
Phase 2
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07385989 Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1… Extranodal NK/T-cell Lymphoma Not Yet Recruiting
Not specified
NCT07764601 R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Primary Central Nervous System Lymphoma Not Yet Recruiting
Disease Areas
DLBCL (1)
Get alerts when WEI XU's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free